← Leaderboards
Jarrod A. Marto
Dana-Farber Cancer Inst
$4,866,870
Attributed
$8,468,783
Total exposure
8
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2013–25$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,468,783 · 8
By mechanism
R01$5,225,345 · 2
R21$1,479,187 · 3
P01$1,086,957 · 1
R61$499,294 · 1
R03$178,000 · 1
Top collaborators
- Nika N. Danial7 shared
- Sara J Buhrlage6 shared
- Alex Kentsis2 shared
- Justin Kim2 shared
Most similar at Dana-Farber Cancer Inst
Same institution · by research overlap
- Hugo Aerts$3,643,476
- Alex Kentsis$10,070,317
- Sara J Buhrlage$3,075,632
- Megha Padi$2,623,509
- Nathanael Schiander Gray$36,761,550
Others in their field
Top investigators on “Mass Spectrum Analysis”
- Paul S. Aisen · Cognition Therapeutics, Inc.$30,310,037
- Reisa A. Sperling · Banner Health$30,310,037
- Richard D Smith · Battelle Pacific Northwest Laboratories$28,842,237
- Ronald C Petersen · Mayo Clinic Coll Of Medicine, Rochester$28,666,849
- David Heimbrook · Leidos Biomedical Research, Inc.$27,692,696
- John Robert Yates · Scripps Research Institute, The$26,948,886
Research focus
Mass Spectrum AnalysisBaseProteinsMalignant NeoplasmsProgramsProteomicsProteomeBiochemicalPathway InteractionsMemberTechnologySmall MoleculeLinkCellsReagentSignal TransductionResponseLeadMetabolicDrug TargetingRegulationCell PhysiologyFamilyInhibitor/Antagonist
Grant awards (23)
New Chemical Tools for Covalent Drug Discovery$249,647
R61 · FY2025 · CA · contact PI
New Chemical Tools for Covalent Drug Discovery$249,647
R61 · FY2024 · CA · contact PI
Novel Screening Platform for Discovery of DUB Targeting Probes$591,626
R01 · FY2022 · CA
(PQ5) Contribution of mitochondrial pathways to metabolic heterogeneity in molecular subtypes of Diffuse Large B Cell Lymphoma$546,861
R01 · FY2022 · CA
Novel Screening Platform for Discovery of DUB Targeting Probes$610,908
R01 · FY2021 · CA
(PQ5) Contribution of mitochondrial pathways to metabolic heterogeneity in molecular subtypes of Diffuse Large B Cell Lymphoma$558,022
R01 · FY2021 · CA
Tools for DUB Drug Discovery$323,910
R21 · FY2021 · CA · contact PI
Core 1: Functional Proteomics$218,574
P01 · FY2021 · CA · contact PI
Novel Screening Platform for Discovery of DUB Targeting Probes$630,805
R01 · FY2020 · CA
(PQ5) Contribution of mitochondrial pathways to metabolic heterogeneity in molecular subtypes of Diffuse Large B Cell Lymphoma$558,022
R01 · FY2020 · CA
Tools for DUB Drug Discovery$323,910
R21 · FY2020 · CA · contact PI
Core 1: Functional Proteomics$218,574
P01 · FY2020 · CA · contact PI
Novel Screening Platform for Discovery of DUB Targeting Probes$629,796
R01 · FY2019 · CA
(PQ5) Contribution of mitochondrial pathways to metabolic heterogeneity in molecular subtypes of Diffuse Large B Cell Lymphoma$541,283
R01 · FY2019 · CA
Core 1: Functional Proteomics$212,015
P01 · FY2019 · CA · contact PI
Tools for the understudied kinase PNK3$178,000
R03 · FY2019 · CA · contact PI
(PQ5) Contribution of mitochondrial pathways to metabolic heterogeneity in molecular subtypes of Diffuse Large B Cell Lymphoma$558,022
R01 · FY2018 · CA
Core 1: Functional Proteomics$218,574
P01 · FY2018 · CA · contact PI
Core 1: Functional Proteomics$219,220
P01 · FY2017 · CA · contact PI
Phosphoproteomic signatures for early detection and stratification of AML$190,852
R21 · FY2016 · CA · contact PI
Phosphoproteomic signatures for early detection and stratification of AML$228,678
R21 · FY2015 · CA · contact PI
Development of deep proteomic sequencing platforms for molecular markers in DLBCL$221,524
R21 · FY2014 · CA
Development of deep proteomic sequencing platforms for molecular markers in DLBCL$190,313
R21 · FY2013 · CA